Pharmaceuticals

Oral Proteins And Peptides Market Insights On Growth Drivers, Trends, And Opportunities

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Oral Proteins And Peptides Market Expected To Reach Based On Its 2026 Value?

The oral proteins and peptides market size has witnessed significant expansion in recent years. It is anticipated to grow from $1.56 billion in 2025 to $1.91 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.5%. The historical growth of this market can be attributed to factors such as the limited oral bioavailability of proteins and peptides, the reliance on injectable formulations, the increasing prevalence of diabetes and gastrointestinal disorders, expanding research into peptide therapeutics, and regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market is projected to experience rapid expansion over the coming years. This market is anticipated to reach $4.26 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.2%. Several factors will contribute to this growth during the forecast period, including the creation of new oral protein delivery methods, the enlargement of chronic disease management initiatives, a growing preference for personalized and combination treatments, increased spending on healthcare for metabolic and hormonal conditions, and the incorporation of digital tools for adherence and monitoring. Key trends anticipated during this period encompass the increasing use of oral insulin and other therapeutic peptides, the expansion of personalized medicine alongside targeted oral protein treatments, a heightened emphasis on therapies for gastrointestinal disorders, the broadening range of oral protein formulations designed for diabetes and metabolic disorders, and innovations in long-acting and combination oral protein products.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19629&type=smp

What Significant Factors Are Influencing The Oral Proteins And Peptides Market Expansion?

The expansion of the biopharmaceutical sector is anticipated to fuel the future development of the oral proteins and peptides market. This industry operates as a segment of the wider pharmaceutical domain, concentrating on the creation, manufacturing, and marketing of medications sourced from biological entities. Its expansion is attributable to breakthroughs in biotechnology, the escalating need for tailored medical treatments, a greater incidence of long-term illnesses, and increased funding for research and development initiatives. Within biopharmaceuticals, oral proteins and peptides present a promising avenue for administering treatments without invasive procedures, thereby improving patient adherence and decreasing reliance on injections. These compounds can target particular ailments, offering better stability and absorption once they enter the digestive system. As an illustration, data from October 2025 by the Bioscience and Health Technology Sector, a UK government statistical source, indicated that during 2023/2024, the UK life sciences industry comprised 6,170 businesses functioning across 7,320 distinct companies. These entities collectively employed 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical sector is a key catalyst for the advancement of the oral proteins and peptides market.

How Is The Oral Proteins And Peptides Market Organized By Segment Classification?

The oral proteins and peptides market covered in this report is segmented –

1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide

2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets

3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action

4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer

Subsegments:

1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)

2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment

3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations

4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)

5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors

What Trends Are Affecting The Growth Of The Oral Proteins And Peptides Market?

Leading companies active in the oral proteins and peptides market are prioritizing the development of innovative formulation technologies to enhance peptide stability, permeability, and bioavailability within oral dosage forms. These advancements are designed to address traditional hurdles like enzymatic degradation and poor absorption within the gastrointestinal tract. For example, in August 2025, BioMed X, a Germany-based biomedical research institute, initiated a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the progress of next-generation oral peptide delivery technologies. This partnership intends to explore novel molecular strategies and delivery mechanisms to enable the creation of safe, effective, and patient-friendly oral peptide therapeutics. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance breakthrough oral drug delivery solutions and expand the therapeutic potential of peptide medicines across metabolic and chronic diseases.

Who Are The Industry Participants Involved In The Oral Proteins And Peptides Market?

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

Get The Full Oral Proteins And Peptides Market Report:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Which Geographic Region Dominates The Oral Proteins And Peptides Market?

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Proteins And Peptides Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-proteins-and-peptides-global-market-report

Browse Through More Reports Similar to the Global Oral Proteins And Peptides Market 2026, By The Business Research Company

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Contraceptive Pills Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-contraceptive-pills-global-market-report

Oral Thin Films Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-thin-films-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795